Director, CHIEF EXECUTIVE OFFICER · Keros Therapeutics, Inc. · Keros Therapeutics, Inc. — Employee Stock Option (right to buy)
Side
A
Value
—
Shares
62.5K
Price
—
Executed
Jan 7, 2026
Disclosed
Jan 9, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 7 executedJan 9, 2026 disclosed
KROS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Keros Therapeutics, Inc. — Employee Stock Option (right to buy)
Ticker
KROS
Shares
62.5K
Price per share
$0
Execution date (reported)
Jan 7, 2026
Owned after transaction
62.5K shares
Days from execution to publication
2
What this establishes
Seehra Jasbir filed this Form 4 reporting a grant or award of KROS on Jan 7, 2026. It became public on Jan 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, CHIEF EXECUTIVE OFFICER
Seehra Jasbircik:0001732369
Issuer
Keros Therapeutics, Inc.cik:0001664710
Revision history · 0
No field has changed since this record was first ingested.
